Answers are grounded in this paper and cite their sources.
Screening of FDA-approved oncology drugs reveals romidepsin's therapeutic potential for osteosarcoma, indicating its efficacy as a histone deacetylase inhibitor.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Seiden et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: